Autoimmune hemolytic anemias (AIHAs) are rare and heterogeneous disorders
characterized by the destruction of red blood cells through warm or cold antibodies. There is …

The introduction of targeted biologic therapies has changed the treatment landscape for
autoimmune diseases (ADs) substantially, but although these therapies provide more …

Hematopoietic stem cell transplantation (HSCT) has evolved for> 20 years as a specific
treatment of patients with autoimmune disease (AD). Using European Society for Blood and …

In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune
diseases (ADs) were published, while an international coordinated clinical programme was …

Background Autologous hematopoietic stem cell transplantation has been used since 1996
for the treatment of severe autoimmune diseases refractory to approved therapies. We …

The diagnosis of autoimmune hemolytic anemia (AIHA) can be made with a stepwise
approach that aims to identify laboratory and clinical evidence of hemolysis and then …

Evans syndrome is an uncommon condition defined by the combination (either
simultaneously or sequentially) of immune thrombocytopenia (ITP) and autoimmune …

Stem cells are a relevant source of information about cellular differentiation, molecular
processes and tissue homeostasis, but also one of the most putative biological tools to treat …

Background Autoimmune haemolytic anaemia is a decompensated acquired haemolysis
caused by the host's immune system acting against its own red cell antigens. The incidence …

Transplantation of haematopoietic stem cells—cells capable of self renewing and
reconstituting all types of blood cell—can treat numerous lethal diseases, including …